- Celldex reported positive results from the phase 1b study using CDX-0159 for the treatment of patients with Chronic Inducible Urticaria; Complete response rate of 95%.
- Expansion opportunity for CDX-0159 exists in that results from a phase 1 study using this drug to treat patients with Chronic Spontaneous Urticaria are expected end of 2021.
- A phase 1 study using CDX-0159 for the treatment of patients with Prurigo Nodularis is expected to start Q4 of 2021.
- Celldex had $176.1 million in cash as of March 31, 2021; Proposed a public offering of common stock of $175 million just the other day; Underwriters given option to purchase up to an additional $26.25 million worth of shares of common stock.
For further details see:
Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The Beginning